Relinquish-M Tablet (Artemisinin 62.50mg + Piperaquine 375mg)

Relinquish‑M Tablet – Full Guide

What Is This?

Relinquish‑M is a fixed‑dose tablet combining Artemisinin (62.5 mg) and Piperaquine (375 mg). It’s used to treat uncomplicated falciparum malaria and, in some cases, uncomplicated P. vivax when resistance to chloroquine exists. The formulation is one of several artemisinin-based combination therapies (ACTs) recommended by the World Health Organization for first-line malaria treatment PubMed Central+3PubMed Central+3GNH India+3. It is manufactured by Kachhela Medex Pvt. Ltd., India Smart Finil+1.

How Does It Work?

Relinquish‑M works through a dual‑mechanism synergy typical of ACTs:

• Artemisinin provides a rapid kill of the malaria parasite during the first days of infection by generating free radicals that damage parasite proteins within infected red blood cells AMHSR+11Wikipedia+11PubMed Central+11.

• Piperaquine, with a longer half‑life, clears remaining parasites and offers a post-treatment prophylactic effect by interfering with parasite metabolism in the digestive vacuole AMHSR+13Wikipedia+13Wikipedia+13.

Together, this combination achieves high cure rates and minimizes the risk of resistance development PubMed CentralPubMed Central.

Benefits

• High Efficacy: Clinical studies report PCR-corrected cure rates of 95–100% at day 28 or day 42 following treatment with similar Artemisinin‑Piperaquine combinations GNH India+6PubMed Central+6clinicaltherapeutics.com+6.

• Fast Parasite and Fever Clearance: Artemisinin rapidly lowers parasitemia and fever; piperaquine maintains clearance longer clinicaltherapeutics.com+1.

• Once-Daily or Short-Course Regimen: Simplicity improves compliance.

• WHO Endorsement: Part of the WHO-recommended ACTs for uncomplicated malaria Wikipedia+10PubMed Central+10ASM Journals+10.

• Low Resistance Risk: Dual action delays resistance development GNH India.

How to Take It?

• Standard Course: 3 days of treatment, once daily dosing. Each dose includes one tablet (62.5 mg artemisinin + 375 mg piperaquine) PubMed Central+1.

• Administration: Take with water, ideally after food to enhance absorption and reduce nausea.

• Pediatric Use: Pediatric formulations exist; dosing must be weight-based and guided by health providers ASM JournalsPubMed Central.

• Missed Dose: If you miss a dose, take it as soon as remembered on the same day; do not double the next dose.

• Avoid monotherapy: Never take artemisinin alone—it promotes resistance Wikipedia.

Who Makes It?

Manufactured by Kachhela Medex Pvt. Ltd., a pharmaceutical company based in India, Relinquish‑M is available as 4 tablets per strip and is often supplied via exports to malaria‑endemic regions Smart Finil+1.

Is It Safe for Humans?

Yes, when used per treatment guidelines. ACTs including artemisinin‑piperaquine are generally safe and well tolerated PubMed Central+1.

Precautions:

• QT Interval: Piperaquine can prolong QT interval—avoid if you have congenital long QT, or are on other QT‑prolonging drugs Wikipediamdpi.com.

• Pregnancy: WHO recommends ACTs in second and third trimesters; first-trimester use only when necessary and alternatives not available Dove Medical Press.

• Drug Interactions: Piperaquine is metabolized via CYP3A4; enzyme inducers like rifampin or carbamazepine may reduce its efficacy mdpi.com.

• Children: Pediatric tolerance appears good, but dosing must be accurate to avoid under- or overdosing ASM Journals.

Side Effects

Most side effects are mild and self-limiting:

Common Effects:

• Nausea, vomiting, abdominal pain, anorexia, dizziness PubMed CentralDove Medical Press.

• Fatigue, headache.

Less Common / Significant:

• QT prolongation, occasionally exceeding 500 ms or >60 ms change from baseline in up to ~10% of patients in trials, though rarely clinically significant mdpi.com+2AMHSR+2.

• Rare allergic reactions, mild liver enzyme elevations, or anemia in rare cases AMHSRWikipedia.

Disclaimer

This information is for educational purposes only and is not medical advice. Relinquish‑M Tablet should only be used under the supervision and prescription of a qualified healthcare provider. It is prescribed for uncomplicated malaria and not intended for prevention, severe malaria, or non-malarial fevers. Misuse can lead to treatment failure or resistance. Always complete the full 3‑day course, do not use artemisinin alone, and consult your doctor if symptoms persist or worsen.